BPI-520105

BPI-520105 is a novel, highly potent small molecule pan-EGFR inhibitor being developed by Betta Pharmaceuticals. As a new chemical entity with full intellectual property rights, it is designed to target a broad spectrum of mutations in the Epidermal Growth Factor Receptor (EGFR). The drug exhibits high selectivity towards multiple EGFR mutations, aiming to address the therapeutic needs of patients with solid tumors that harbor these genetic alterations. BPI-520105 is intended to overcome resistance mechanisms seen with earlier-generation EGFR inhibitors. It is currently in the IND-enabling preclinical stage of development.